tiprankstipranks
Advertisement
Advertisement

ALMS Stock Latest News

Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target
RatingsAlumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target
5d ago
ALMS
Alumis Shareholders Reelect Directors and Ratify Auditor
PremiumCompany Announcements
Alumis Shareholders Reelect Directors and Ratify Auditor
1M ago
8K
ALMS
Alumis Highlights TYK2 Strategy in Updated Investor Presentation
PremiumCompany Announcements
Alumis Highlights TYK2 Strategy in Updated Investor Presentation
1M ago
8K
ALMS
Alumis management to meet with Cantor
PremiumThe Fly
Alumis management to meet with Cantor
1M ago
ALMS
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
PremiumTipRanks Newswire
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
2M ago
ALMS
NVCT
Alumis rises 10.3%
PremiumThe FlyAlumis rises 10.3%
2M ago
ALMS
Alumis price target raised to $40 from $38 at Chardan
Premium
The Fly
Alumis price target raised to $40 from $38 at Chardan
3M ago
ALMS
Alumis Inc. (ALMS) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Alumis Inc. (ALMS) Q1 Earnings Cheat Sheet
3M ago
ALMS
Alumis price target raised to $39 from $38 at Morgan Stanley
PremiumThe Fly
Alumis price target raised to $39 from $38 at Morgan Stanley
3M ago
ALMS
Alumis price target raised to $51 from $49 at Wells Fargo
PremiumThe Fly
Alumis price target raised to $51 from $49 at Wells Fargo
3M ago
ALMS
Alumis price target raised to $34 from $32 at Guggenheim
PremiumThe Fly
Alumis price target raised to $34 from $32 at Guggenheim
3M ago
ALMS
Alumis downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Alumis downgraded to Neutral from Buy at H.C. Wainwright
3M ago
ALMS
Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
PremiumThe FlyAlumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
3M ago
ALMS
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target
Premium
Ratings
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target
4M ago
ALMS
Alumis falls -16.1%
Premium
The Fly
Alumis falls -16.1%
4M ago
ALMS
Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
PremiumRatings
Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
4M ago
ALMS
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
PremiumThe Fly
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
4M ago
JNJ
TAK
Alumis price target raised to $55 from $50 at Oppenheimer
PremiumThe Fly
Alumis price target raised to $55 from $50 at Oppenheimer
4M ago
JNJ
TAK
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
PremiumCompany Announcements
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
4M ago
8K
ALMS
Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
PremiumRatingsAlumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
4M ago
ALMS
Alumis price target lowered to $25 from $40 at H.C. Wainwright
Premium
The Fly
Alumis price target lowered to $25 from $40 at H.C. Wainwright
4M ago
ALMS
Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
Premium
The Fly
Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
4M ago
ALMS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >